- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05921227
Addressing Treatment Nonresponders
July 25, 2025 updated by: University of Arizona
Identification of Treatment Parameters the Maximize Language Treatment Efficacy for Children
The goal of this clinical trial is to see if providing late talking toddlers who are not responding to the Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment with a different way of communicating will help them improve their word learning.
Participants will start with VAULT word learning treatment.
If, in the first few sessions, it looks like they won't respond well, they will be provided with a Big Mack Augmentative and Alternative Communication device (a button that says a word when you press it) to use for their responses.
The investigators will see if this modification will help with word learning.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Children will begin Vocabulary Acquisition and Usage for Late Talkers (VAULT) word learning treatment.
If, after three sessions, they do not show an initial response to treatment, they will be provided with a Big Mack Augmentative and Alternative Communication device which will allow them to 'say' the treatment words with the device.
Treatment will continue until the children have had 8 total weeks of treatment (2x/wk for 30 minutes per session).
The investigators will measure word learning across time tracking both spoken productions and productions made with the device.
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mary Alt, PhD
- Phone Number: 520-626-6180
- Email: malt@arizona.edu
Study Contact Backup
- Name: Nora Evans-Reitz, m
- Phone Number: 520-626-6885
- Email: nevansreitz@arizona.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Native English Speaking
- Pass pure tone hearing screening or medical report of normal hearing
- 2-3 years at start of study
- MacArthur-Bates Communicative Development Inventories (MCDI) expressive scale <10th percentile
Exclusion Criteria:
- Parental report of other diagnoses
- Enrolled in concurrent treatment elsewhere
- Nonverbal IQ <75 as measured by the Bayley Scales
- Parents unable to consistently bring child to treatment sessions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Alternative Treatment Including Augmentative and Alternative Communication
Once children are shown to not respond to the usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment, they will be placed in this arm, which will train them to use an Augmentative and Alternative Communication device as an additional means to use to 'say' a word.
|
VAULT is an input-based word learning intervention based on principles of statistical learning.
|
|
Active Comparator: Usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment
Children who do appear to respond to treatment will continue with the full course of usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) intervention.
|
VAULT is an input-based word learning intervention based on principles of statistical learning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Effect Size
Time Frame: Change from baseline through treatment, which will average an 8-week time frame.
|
The investigators will count the number of spontaneous and probed productions of target and control words and calculate a treatment effect size (d).
|
Change from baseline through treatment, which will average an 8-week time frame.
|
|
Number/Rate of words learned
Time Frame: Change from Initial Evaluation through Follow-up, which will average a 6-month time frame.
|
The investigators will measure the number of words learned and rate of words learned as reported by the parent on the MCDI starting prior to treatment and measured during, immediately following, and 4-6 weeks after the treatment.
|
Change from Initial Evaluation through Follow-up, which will average a 6-month time frame.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post Treatment Retention
Time Frame: Change from end of treatment to follow up, which will average 4-6 weeks.
|
We will use probe data or specific words and parental report to determine how many of the words the child retained from treatment.
|
Change from end of treatment to follow up, which will average 4-6 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mary Alt, PhD, University of Arizona
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
August 1, 2027
Study Registration Dates
First Submitted
June 14, 2023
First Submitted That Met QC Criteria
June 26, 2023
First Posted (Actual)
June 27, 2023
Study Record Updates
Last Update Posted (Actual)
July 30, 2025
Last Update Submitted That Met QC Criteria
July 25, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Late Talker Phase 6
- 2R01DC015642-06 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Language Development Disorders
-
IRCCS Eugenio MedeaRecruitingLearning Disabilities | Development, Infant | Developmental Language Disorder | Development, LanguageItaly
-
Women and Infants Hospital of Rhode IslandCompletedAdolescent Behavior | Language Development | Development, Child | Language Delay
-
IRCCS Eugenio MedeaEnrolling by invitationLanguage Development Disorders | Infant Development | Language Development | InterventionItaly
-
IRCCS Eugenio MedeaBasque Center on Cognition, Brain and Language (BCBL)RecruitingLanguage Development Disorders | Infant Development | Language Development | Infant Developmental AssessmentItaly
-
Université Catholique de LouvainNot yet recruitingUnderstanding the Predictive Factors and the Neurocognitive Basis of Developmental Language DisorderLanguage Development | Developmental Language DisordersBelgium
-
IRCCS Centro Neurolesi Bonino PulejoEnrolling by invitationDevelopment Language DisorderItaly
-
Purdue UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingLanguage Development | Developmental Language Disorder | Specific Language ImpairmentUnited States
-
Purdue UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedLanguage Development | Developmental Language Disorder | Specific Language ImpairmentUnited States
-
Purdue UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingDevelopmental Language Disorder and Language Impairment | Language Development | Specific Language ImpairmentUnited States
-
University of TorontoGeorgetown University; Children's Hospital Medical Center, Cincinnati; University... and other collaboratorsRecruitingLanguage Development | Developmental Language Disorder | Language DelayCanada
Clinical Trials on VAULT Phase 6
-
University of ArizonaNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
University of ArizonaNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Charitable Union for the Research and Education...RecruitingErectile Dysfunction Following Radical ProstatectomyUnited States
-
University of ChicagoCompletedHypoxia | SARS-CoV-2 Acute Respiratory Disease | Carotid BodiesUnited States
-
University of CalgaryCanadian Institutes of Health Research (CIHR); The MSI FoundationRecruitingPelvic Organ ProlapseCanada
-
University of AarhusUnknownRecurrence | Uterine Cervical Neoplasms | Human Papilloma VirusDenmark
-
Università degli Studi dell'InsubriaNot yet recruiting
-
Rawane El DimachkiSorbonne UniversityCompletedAnalgesic Effects of MusicLebanon
-
Azienda Ospedaliero-Universitaria di ParmaRecruitingPostoperative Complications | Vaginal Cuff Dehiscence | Gynecologic CancersItaly
-
New York Institute of TechnologyCompletedCervical DysfunctionUnited States